Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | RBP4 | P02753 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809457 | 0.77 | EPHX2 (0.47) | CNR1EPHX2MGLL | |
| SCHEMBL1806855 | 0.76 | EPHX2 (0.46) | CNR1EPHX2MGLL | |
| SCHEMBL1810791 | 0.73 | MDM2 (0.59) | MGLLRBP4 | |
| SCHEMBL1809331 | 0.72 | RBP4 (0.60) | CNR1EPHX2RBP4 | |
| SCHEMBL12099686 | 0.71 | SCD (0.42) | CNR1 | |
| SCHEMBL1806936 | 0.71 | CNR1 (0.48) | CNR1EPHX2MGLL | |
| SCHEMBL1808901 | 0.70 | MGLL (0.63) | EPHX2MGLL | |
| SCHEMBL1811372 | 0.70 | PRKAA2 (0.51) | EPHX2MGLL | |
| SCHEMBL4123723 | 0.70 | POLB (0.45) | TRPV1RBP4 | |
| SCHEMBL4280881 | 0.70 | HSD11B1 (0.44) | TRPV1RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | claimed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | claimed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | claimed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | CNR1 149/4885EPHX2 2869/4885TRPV1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.